Phase II Study of Taselisib in PIK3CA Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCIMATCH ECOG-ACRIN Trial (EAY131) Subprotocol I

Ian E. Krop, Opeyemi A. Jegede, Juneko E. Grilley-Olson, Josh D. Lauring, Edith P. Mitchell, James A. Zwiebel, Robert J. Gray, Victoria Wang, Lisa M. McShane, Larry V. Rubinstein, David Patton, P. Mickey Williams, Stanley R. Hamilton, Scott A. Kono, James M. Ford, Agustin A. Garcia, Xingwei D. Sui, Robert D. Siegel, Brian M. Slomovitz, Barbara A. ConleyCarlos L. Arteaga, Lyndsay N. Harris, Peter J. O'Dwyer, Alice P. Chen, Keith T. Flaherty

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Fingerprint

Dive into the research topics of 'Phase II Study of Taselisib in PIK3CA Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCIMATCH ECOG-ACRIN Trial (EAY131) Subprotocol I'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science